Iguratimod has also been reported to induce a reduction in anti-type II collagen antibodies, i.e., IgGa2 and IgM, without affecting the IgM concentration in serum.30 This antiantibody effect is directly linked to its cartilage and bone destruction prevention effects during the treatment of RA. The gene discussed is CD40LG; the disease is rheumatoid arthritis.